Results 31 to 40 of about 6,313 (203)

Cost analysis of insulin degludec in comparison with insulin detemir in treatment of children and adolescents with type 1 diabetes in the UK

BMJ Open Diabetes Research & Care, 2019
Objective With healthcare systems under increasing financial pressure from costs associated with diabetes care, it is important to assess which treatments provide clinical benefits and represent best value.
Nandu Thalange, Jens Gundgaard, Witesh Parekh, Deniz Tutkunkardas   +3 more
doaj   +1 more source

Characterisation of insulin analogues therapeutically available to patients [PDF]

, 2018
The structure and function of clinical dosage insulin and its analogues were assessed. This included ‘native insulins’ (human recombinant, bovine, porcine), ‘fast-acting analogues’ (aspart, glulisine, lispro) and ‘slow-acting analogues’ (glargine ...
Adams, Gary G., Alzahrani, Qushmua E., Ballance, Simon, Besong, David T.M., Chayen, Naomi, Gillis, Richard B., Harding, Stephen E., Jiwani, Shahwar I., Kok, M. Samil, Lithgo, Ryan, Meal, Andrew, Morgan, Paul S., Zobel, Hanne   +12 more
core   +5 more sources

Clinical use of the co-formulation of insulin degludec and insulin aspart [PDF]

, 2016
AimsTo provide a review of the available data and practical use of insulin degludec with insulin aspart (IDegAsp). Premixed insulins provide basal and prandial glucose control; however, they have an intermediate-acting prandial insulin component and do ...
A., A., A., A. G., G., G. R., J., J. S., K., Kumar, L., M., M., P. D., R., R., S., S. C., T., T.   +19 more
core   +1 more source

Cost-effectiveness of insulin degludec versus insulin glargine U100 in adults with type 1 and type 2 diabetes mellitus in Bulgaria

BMC Endocrine Disorders, 2019
Background This analysis evaluates the cost-effectiveness of insulin degludec (degludec) versus biosimilar insulin glargine U100 (glargine U100) in patients with type 1 (T1DM) and type 2 diabetes mellitus (T2DM) in Bulgaria.
Monika Russel-Szymczyk, Vasil Valov, Alexandra Savova, Manoela Manova   +3 more
doaj   +1 more source

Insulin degludec overdose in an adolescent with type 1 diabetes: proactive management including monitoring using the Freestyle Libre flash glucose monitoring system

Endocrinology, Diabetes & Metabolism Case Reports, 2018
An adolescent with type 1 diabetes and a history of self-harm, which included intentional overdoses and insulin omission, presented with an insulin degludec overdose.
Harmony Thompson, Helen Lunt, Cate Fleckney, Steven Soule   +3 more
doaj   +1 more source

A meta-analysis of rate ratios for nocturnal confirmed hypoglycaemia with insulin degludec vs. insulin glargine using different definitions for hypoglycaemia [PDF]

, 2016
Aims: A prospective meta-analysis of phase 3 trials showed lower rates of nocturnal hypoglycaemia with insulin degludec vs. insulin glargine. We investigated the consistency of the results across different definitions of hypoglycaemia.
Bode, Brod, Brod, Evans, Evans, Evans, Garber, Gough, Heise, Heise, Heller, Hollander, Landstedt-Hallin, Mathieu, Meneghini, Onishi, Ratner, Rodbard, Seaquist, Wright, Zinman   +20 more
core   +1 more source

National advisory board on diabetes mellitus: unsolved issues and new opportunities for diabetes treatment

Сахарный диабет, 2014
In June 2014, the national experts on diabetes mellitus discussed the opportunities to improve the efficacy and outcomes of diabetes treatment using the strategy of patient-oriented care in diabetes.
Gagik Radikovich Galstyan
doaj   +1 more source

Switching from Insulin Degludec plus Dipeptidyl Peptidase-4 Inhibitor to Insulin Degludec/Liraglutide Improves Glycemic Variability in Patients with Type 2 Diabetes: A Preliminary Prospective Observation Study

Journal of Diabetes Research, 2022
Incretins reduce glycemic variability (GV) in patients with type 2 diabetes, but it is unknown whether switching from a combination of basal insulin and a DPP-4 inhibitor to insulin degludec/liraglutide (IDegLira) improves GV. We performed an exploratory
Yuki Oe, Hiroshi Nomoto, Akinobu Nakamura, Saki Kuwabara, Yuka Takahashi, Ayano Yasui, Rimi Izumihara, Aika Miya, Hiraku Kameda, Kyu Yong Cho, Tatsuya Atsumi, Hideaki Miyoshi   +11 more
doaj   +1 more source

IDegLira Versus Insulin Glargine U100: A Long-term Cost-effectiveness Analysis in the US Setting [PDF]

, 2017
Article full text The full text of this article can be found here. Provide enhanced digital features for this article If you are an author of this publication and would like to provide additional enhanced digital features for your article then please ...
Barnaby Hunt, Jakob Langer, Michelle Mocarski, William J. Valentine   +3 more
core   +2 more sources

Evaluating the long-term cost-effectiveness of fixed-ratio combination insulin degludec/liraglutide (IDegLira) versus other treatment regimens in the chinese type 2 diabetes patients

Diabetology & Metabolic Syndrome, 2023
Background and aims To assess the cost-effectiveness of utilizing IDegLira in comparison to other treatment regimens ( liraglutide and degludec) in managing type 2 diabetes, taking into account the Chinese healthcare system’s perspective.
Ran Wei, Weihao Wang, Xiusheng Huang, Jingtao Qiao, Jinghe Huang, Chang Xing, Qi Pan, Lixin Guo   +7 more
doaj   +1 more source